Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

FST-100 in the Treatment of Acute Viral Conjunctivitis

This study has been completed.
Information provided by (Responsible Party):
Foresight Biotherapeutics Identifier:
First received: October 24, 2011
Last updated: August 28, 2014
Last verified: August 2014

October 24, 2011
August 28, 2014
May 2013
February 2014   (final data collection date for primary outcome measure)
Clinical resolution of acute viral conjunctivitis [ Time Frame: 6-7 days ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01461954 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
FST-100 in the Treatment of Acute Viral Conjunctivitis
A Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Viral Conjunctivitis

This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis. The study intends to show superiority of FST-100 ophthalmic suspension compared to vehicle for clinical resolution of acute viral conjunctivitis.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Acute Viral Conjunctivitis
  • Drug: FST-100
  • Drug: FST-100 Vehicle
    FST-100 Vehicle
  • Experimental: FST-100
    Intervention: Drug: FST-100
  • Placebo Comparator: FST-100 Vehicle
    Intervention: Drug: FST-100 Vehicle
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a clinical diagnosis of suspected acute viral conjunctivitis in at least one eye

Exclusion Criteria:

  • Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Brazil
Foresight Biotherapeutics
Foresight Biotherapeutics
Not Provided
Study Director: Aron Shapiro ORA, Inc.
Foresight Biotherapeutics
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP